This consultation closed on 29 September 2021. Results were published to the consultation hub on 15 December 2021.
The Therapeutic Goods (Permissible Ingredients) Determination ('the Determination') is a legislative instrument made under section 26BB of the Therapeutic Goods Act 1989 ('the Act'). This instrument specifies all of the ingredients that are available for use in listed medicines and the requirements for their use. The Determination is continually reviewed by the TGA to ensure that all ingredients are safe for use in low-risk medicines.
Allergen statement for mollusc-derived ingredients.
Peripheral neuropathy associated with lower dose vitamin B6.
Risk to infants from nasal use of benzalkonium chloride.
Artemisinin and pregnancy risk.
For more information on the proposals, and to participate in the consultation, please visit the consultation hub.
The consultation opened on Wednesday 4 August 2021. Interested parties responded by close of business Wednesday 29 September 2021. The response time was extended to accommodate disruptions due to state-wide lockdowns throughout Australia.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.